

DAFTAR PUSTAKA

1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int.* 2024;105(4S):S117-S314.
2. Madero M, Levin A, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK, et al. Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2024 Clinical Practice Guideline. *Ann Intern Med.* 2025;178(5):705-713.
3. Badura K, Janc J, Wąsik J, Gnitecki S, Skwira S, Młynarska E, et al. Anemia of Chronic Kidney Disease—A Narrative Review of Its Pathophysiology, Diagnosis, and Management. *Biomedicines.* 2024; 12(6):1191.
4. Babitt JL, Berns JS, Bozkurt B, Khedairy RSC, Cuevas Y, Effa EE, et al. Executive Summary of the KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD). *Kidney Int.* 2026;109(1):44-56.
5. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO 2026 clinical practice guideline for the management of anemia in chronic kidney disease (CKD). *Kidney Int.* 2026;109(1S):S1-S99.
6. Mark P, Stafford L, Grams M et al. Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023 *The Lancet*, 2025; 406, 2461-2482
7. Hidayangsih PS, Tjandrarini DH, Sukoco NEW, Sitorus N, Dharmayanti I, Ahmadi F. Chronic kidney disease in Indonesia: evidence from a national health survey. *Osong Public Health Res Perspect.* 2023;14(1):23-30.
8. Hustrini NM, Susalit E, Harimurti K, Haryoso IS, Legrans AE, Damarjati K, et al. Prevalence, incidence and risk factors of chronic kidney disease in people with diabetes and hypertension in Indonesia: a multicentre cross-sectional study. *BMJ Open.* 2025;15(10):e103779.
9. Awdishu L, Maxson R, Gratt C, Rubenzik T, Battistella M. KDIGO 2024 clinical practice guideline on evaluation and management of chronic kidney disease: A primer on what pharmacists need to know. *Am J Health Syst Pharm.* 2025;82(12):660-671.
10. Hu R, Zhao Z, Xie L, Ma Z, Wu W, Li S. Global, regional, and national burden of chronic kidney disease due to diabetes mellitus type 2 from 1990 to 2021, with projections to 2036: a systematic analysis for the Global Burden of Disease Study 2021. *Front Med (Lausanne).* 2025;12:1531811. Published 2025 Feb 17.

11. Kim D, Lee J, Toyama T, Liyanage T, Woodward M, Matsushita K, et al. Prevalence and treatment patterns of anaemia in individuals with chronic kidney disease across Asia: a systematic review and meta-analysis. *Nephrology (Carlton)*. 2025;30(2):e70002.
12. Handrean IGE, Putra MN IMM, Pratama Putra IGL. Patterns and predictors of anaemia in haemodialysis patients: relationship with comorbidities and dialysis exposure time. *MEDISAINS: Jurnal Ilmiah Ilmu-Ilmu Kesehatan*. 2025;23(3):165–170.
13. Hain D, Bednarski D, Cahill M, Dix A, Foote B, Haras MS, et al. Iron-Deficiency Anemia in CKD: A Narrative Review for the Kidney Care Team. *Kidney Med*. 2023;5(8):100677.
14. Navaneethan SD, Bansal N, Cavanaugh KL, Chang A, Crowley S, Delgado C, et al. KDOQI US Commentary on the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD. *Am J Kidney Dis*. 2025;85(2):135-176.
15. Levin A, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK, et al. Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns. *Kidney Int*. 2024;105(4):684-701.
16. Ortiz A, Lees JS, Torra R, Stel VS, Kramer A, Mark PB. The updated global burden of chronic kidney disease: one death every 20 seconds. *Nephrol Dial Transplant*. 2026;41(1):1-3.
17. Xie K, Cao H, Ling S, Zhong J, Chen H, Chen P, et al. Global, regional, and national burden of chronic kidney disease, 1990-2021: a systematic analysis for the global burden of disease study 2021. *Front Endocrinol (Lausanne)*. 2025;16:1526482.
18. Hustrini NM, et al. Chronic kidney disease epidemiology and risk factors in Indonesia. *Indones J Nephrol*. 2025; (in press).
19. Portolés J, Martín L, Broseta JJ and Cases A. Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents. 2021 *Front. Med*. 8:642296.
20. Norregaard R, Mutsaers HAM, Frokiaer J, Kwon TH. Obstructive nephropathy and molecular pathophysiology of renal interstitial fibrosis. *Physiological Reviews*. 2023;103(4):2847–2892.
21. Ammar A, Trabelsi K, Hermassi S, Kolahi A, Mansournia MA, Jahrami H, et al. Global disease burden attributed to low physical activity in 204 countries and territories from 1990 to 2019: Insights from the Global Burden of Disease 2019 Study. *Biology of Sport*. 2023;40(3):835-855.
22. Ueda N, Takasawa K. Impact of inflammation on ferritin, hepcidin and the

management of iron deficiency anemia in chronic kidney disease. *Nutrients*. 2018;10(9):1173.

23. Hashmi MF, Shaikh H, Rout P. Anemia of Chronic Kidney Disease. [Updated 2024 Jul 23]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK539871/>.
24. Bissinger R, Schaefer L, Bohnert BN, Schork A, Hoerber S, Peter A. GFR is a Key Determinant of Red Blood Cell Survival in Anemia Associated With Progressive CKD. *Kidney International Reports*. 2025;10:730-742.
25. Eisenga MF, et al. Iron deficiency and anemia in CKD: new insights from the KDIGO 2026 guideline. *Kidney Int*. 2026;109(2):189-201.
26. Laville SM, Conturier A, Lambert O, Metzger M, Mansencal N, Jacquelinet C, et al. Urea Levels and cardiovascular disease in patients with chronic kidney disease. *Nephrol Dial Transplant*. 2023;38(1):92-184
27. Iatrudi F, et al. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease: a commentary from the European Renal Best Practice. *Nephrol Dial Transplant*. 2025;40(2):273-282.
28. Tanaka T, et al. Molecular mechanisms of erythropoietin deficiency in chronic kidney disease. *Kidney Int*. 2025; (supplement).
29. Webb HT, et al. Impact of anemia pharmacotherapy on chronic kidney disease progression: what is the evidence? *Expert Opin Pharmacother*. 2025;26(3):289-302.
30. Wang AY, et al. Management of anemia in CKD: focus on hypoxia-inducible factor stabilizers. *Curr Opin Nephrol Hypertens*. 2025;34(1):45-52
31. Yan S, Jinwei W, Jing Y, Li Y, Fangfang Y, Xiaolei W, et al. Anemia among Chinese patients with chronic kidney disease and its association with quality of life - results from the Chinese cohort study of chronic kidney disease (C-STRIDE). *BMC Nephrol*. 2021;22(64).
32. Canney M, Induruwage D, Tang M, Alencar de Pinho N, Er L, Zhao Y, et al. Regional variation in hemoglobin distribution among individuals with chronic kidney disease: the ISN International Network of CKD (iNET-CKD) Cohorts. *Kidney Int Rep*. 2023;8(10):2056-2067.
33. Yi SW, Moon SJ, Yi JJ. Low normal hemoglobin levels and anemia are associated with increased risk of end-stage renal disease in general populations: a prospective cohort study. *PLoS One*. 2019;14(4):e0215920.

34. Sofue T, Nakagawa N, Kanda E, Nagasu H, Matsushita K, Nangaku M, et al. Prevalence of anemia in patients with chronic kidney disease in Japan: a nationwide cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB). *PLoS One*. 2020;15(7):e0236132.
35. Han SY, Oh SW, Hong JW, Yi SY, Noh JH, Lee HR, et al. Association of estimated glomerular filtration rate with hemoglobin level in Korean adults: the 2010–2012 Korea National Health and Nutrition Examination Survey. *PLoS One*. 2016;11(4):e0150029.
36. Lamerato L, et al. Epidemiology and outcomes in patients with anemia of chronic kidney disease not on dialysis from a large US healthcare system database: a retrospective observational study. *BMC Nephrol*. 2022;23:178.
37. Vestergaard SV, Heide-Jørgensen U, van Haalen H, et al. Anemia in patients with non-dialysis-dependent chronic kidney disease: prevalence, incidence and clinical outcomes. *Clin Epidemiol*. 2020;12:967-978.
38. Wande IN, Dewi DAPR, Sari NKP. Correlation of sTfR, Hemoglobin, Serum Iron, and eGFR in Pre-dialysis CKD Patients at Sanglah Hospital. *Indonesian Journal of Clinical Pathology and Medical Laboratory*. 2023 Jul;29(3):211-215
39. Adera H, et al. Prevalence of anemia and its associated factors among chronic kidney disease patients. *Int J Nephrol Renovasc Dis*. 2019;12:219-228.
40. Shen J, et al. Anemia among Chinese patients with chronic kidney disease and its association with quality of life: results from the Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE). *BMC Nephrol*. 2021;22:85.
41. Mori Y, et al. Impact of anemia on renal outcomes in elderly patients with chronic kidney disease: a cohort study. *Clin Exp Nephrol*. 2024.
42. Santos S, Lousa I, Sameiro-Faria M, Santos-Silva, A, Belo, L. Mechanisms of Anemia in Elderly Patients with Chronic Kidney Disease. *Preprints*. 2025.
43. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. *KDIGO 2025 Clinical Practice Guideline for Anemia in Chronic Kidney Disease*. *Kidney Int*. 2025;107(5 Suppl):S1–S250.
44. Babitt JL, Lin HY. Mechanisms of anemia in CKD. *J Am Soc Nephrol*. 2012;23(10):1631–1634.
45. Stauffer ME, Fan T. Prevalence of anemia in chronic kidney disease in the United States. *PLoS One*. 2014;9(1):e84943.
46. Fishbane S, Spinowitz B. Update on anemia in ESRD and earlier stages of

CKD: Core curriculum 2018. Am J Kidney Dis. 2018;71(3):423–435.

47. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. *KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease*. Kidney Int. 2024;105(4 Suppl):S1–S150.



